Related Experiment Video

Updated: Jan 4, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer

Monica Benvenuto1, Chiara Focaccetti2, Valerio Izzi3

  • 1Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy; Saint Camillus International University of Health and Medical Sciences, via di Sant'Alessandro 8, 00131, Rome, Italy.

Seminars in Cancer Biology
|November 8, 2019
PubMed

Insights

Neoantigens offer a promising avenue for breast cancer immunotherapy by targeting unique tumor mutations. This review explores neoantigen discovery, heterogeneity, and recent advancements in targeting these antigens for effective cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Breast cancer is a leading cause of cancer mortality in women due to its heterogeneity and low immunogenicity.
  • Cancer immunotherapy aims to stimulate the host immune system against cancer cells using tumor antigens.
  • Neoantigens are ideal targets due to their tumor specificity, lack of expression in healthy tissues, and ability to overcome immune tolerance.

Purpose of the Study:

  • To review technologies for neoantigen discovery in breast cancer.
  • To discuss the heterogeneity of neoantigens within breast cancer.
  • To highlight recent advancements in neoantigen-targeted breast cancer immunotherapy.

Main Methods:

  • Review of scientific literature on neoantigen discovery technologies.
  • Analysis of studies investigating neoantigen heterogeneity in breast cancer.
  • Synthesis of recent research on immunotherapies targeting neoantigens.

Main Results:

  • Neoantigens are tumor-specific and elicit strong T cell and B cell responses.
  • Understanding neoantigen heterogeneity is crucial for effective immunotherapy design.
  • Recent studies show promise in targeting neoantigens for breast cancer treatment.

Conclusions:

  • Neoantigens represent a significant fraction of targets for tumor-infiltrating T cells.
  • Targeting neoantigens holds potential for personalized and effective breast cancer immunotherapy.
  • Further research into neoantigen discovery and therapeutic strategies is warranted.
Keywords:
Cancer vaccineImmune responseImmunotherapyNeoantigens

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K